

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- | | |
|--------------------------|--|
| n/a | Confirmed |
| ☐ | ☒ The exact sample size (<i>n</i>) for each experimental group/condition, given as a discrete number and unit of measurement |
| ☐ | ☒ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| ☐ | ☒ The statistical test(s) used AND whether they are one- or two-sided
<i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i> |
| ☐ | ☒ A description of all covariates tested |
| ☐ | ☒ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| ☐ | ☒ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| ☐ | ☒ For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted
<i>Give P values as exact values whenever suitable.</i> |
| ☐ | ☒ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| ☐ | ☒ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| ☐ | ☒ Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated |

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection	This study involved 1,506 unique <i>A. baumannii</i> isolates from more than 54 thousand BSI patients whose data were collected via the National Surveillance for Blood Bacterial Resistant Investigation Collaborative System (BRICS) between January 2011 and December 2021 from 76 secondary and tertiary hospitals distributed across 25 provinces in China.
Data analysis	Prokka (version 1.13.0),mlst (version 2.19.0),Kaptive (version 2.0.7), ISfinder, ICEberg,PHASTER,Islandviewer4, Roary (Version 3.12.0), CD-HIT (Version 4.7.0), phytools (Version 2.1-1), BEAST (version 2.7.4),SPAdes (version 3.11.1),Gubbins (version 2.4.1),Snippy (version 4.6.0), RaxML (version 8.2.12),iTOL (version 6.9),RASP (Version 4.0). We have described the software and code used during data analysis in the manuscript and uploaded them at the following link: https://github.com/ChangMengru/BSIAB_Population_in_China .

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

Processed data are available in Supplementary data 1. The sequencing datasets generated in this study were publicly available in the NCBI database (BioProject: PRJNA1120174). Source data are provided as a Source Data file.

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender	not applicable
Reporting on race, ethnicity, or other socially relevant groupings	not applicable
Population characteristics	not applicable
Recruitment	not applicable
Ethics oversight	The sample collection protocol was approved by the institutional review board of the First Affiliated Hospital of Zhejiang University in China (Reference number: IIT20210311B).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	The determination of sample size has been described in the relevant sections of the manuscript.
Data exclusions	No data were excluded from the analyses.
Replication	To verify the reproducibility of the results, we performed three biological replicates.
Randomization	All experimental groups were randomly assigned.
Blinding	All experiments were conducted in a blinded manner.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
☒	☐ Antibodies
☒	☐ Eukaryotic cell lines
☒	☐ Palaeontology and archaeology
☐	☒ Animals and other organisms
☒	☐ Clinical data
☒	☐ Dual use research of concern
☒	☐ Plants

Methods

n/a	Involved in the study
☒	☐ ChIP-seq
☒	☐ Flow cytometry
☒	☐ MRI-based neuroimaging

Animals and other research organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

Laboratory animals	mice
Wild animals	n/a.
Reporting on sex	n/a.
Field-collected samples	confirmed.
Ethics oversight	The sample collection protocol was approved by the institutional review board of the First Affiliated Hospital of Zhejiang University in China.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Plants

Seed stocks	n/a.
Novel plant genotypes	n/a.
Authentication	n/a.